Here’s why analysts are playing it cautiously optimistic on the struggling pharmaceutical giant.
Analyst warns that investors betting on Himax are naïve to bearish risks circling overhead.
Ambarella’s computer vision chips present enticing long-term possibilities, says Oppenheimer.
Sales reorganization initiatives and improved execution levels are encouraging, says analyst.
Nutanix posts record high 45% rise in software sales.
Analyst Expects More Upside Later in Fiscal 2018 and Fiscal 2019
The Medicines Company’s Vabomere – A Solid Option for CarbapenemResistant cUTIs: Oppenheimer
Yesterday, at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, The Medicines Company …
Focusing on DIY Fitness Crowd Is a Good Start, Says Analyst
On the heels of a solid fiscal first quarter beat from Alibaba Group Holding Ltd …